A clinical research coordinator at a mid-sized academic site pulls up her CTMS on a Tuesday morning and sees the same thing she saw last Tuesday: seventeen patients flagged as potentially eligible for the oncology study that opened eight weeks ago. Four have been contacted. Two responded. One screened. None enrolled. The sponsor’s enrollment dashboard shows the site as “active.” The CRA’s last monitoring visit report lists no critical findings. On paper, the site is performing. In practice, the pipeline is leaking from the first step.
That scenario is not an edge case. According to a recent survey reported by FierceBiotech, 59% of clinical trial sites are seeing fewer eligible patients recruited because of inefficiencies in their recruitment process. More than half. That number does not describe a handful of underperforming sites dragging down a strong network — it describes a systemic failure baked into how most sites run their intake workflows.
Where the Workflow Actually Breaks
The word “inefficiency” in that finding is doing a lot of work, and it is worth unpacking what it actually means at the site level. Most recruitment conversations focus on two variables: whether enough patients exist in the catchment area, and whether the sponsor has invested in outreach. Both matter. But the 59% figure points at something different — patients who are theoretically reachable but who never make it through the operational steps between initial identification and first visit. That gap lives inside the site’s own walls.
The WCG 2024 Clinical Research Site Challenges Report, which surveyed 852 clinical research sites globally, found that 39% of sites identified participant recruitment and retention as a top challenge — and that study startup remained a consistent pressure point, cited by 35% of sites. Those two findings belong together. Sites that struggle to activate cleanly almost always carry that instability forward into enrollment. A delayed SIV means the coordinator who trained on the protocol has rotated off. A budget amendment that took six weeks to execute means the screening log template was never finalized before the sponsor expected first-patient-in. The startup dysfunction does not resolve at activation; it metastasizes into recruitment paralysis.
The economics behind that paralysis are punishing. The Tufts Center for the Study of Drug Development updated its day-of-delay analysis in 2023, finding that a single day of delay in drug development costs approximately $800,000 in unrealized prescription drug sales and $40,000 in direct daily clinical trial costs. Sites running recruitment workflows that add even two to three weeks of friction to the identification-to-screen timeline are not just missing enrollment targets — they are compounding a cost that most sponsors have never run the arithmetic on at the site level.
The operational artifact that surfaces this problem fastest is the screening log. Pull the screening log from any site where recruitment is flagged as slow and look at three columns: date of initial eligibility flag, date of first patient contact attempt, and date of screen failure reason recorded. In sites I work with across the CliniBiz network, the gap between column one and column two is often ten to fourteen days. That is not a patient availability problem. That is a coordinator bandwidth problem, a contact workflow problem, or a CTMS configuration problem — and none of those show up in a monitoring visit unless the CRA is specifically looking for them.
The Sponsor-Site Contract Problem Nobody Wants to Name
Here is the counterintuitive piece that most operational conversations miss: sponsors fund enrollment, but they rarely fund the workflow that produces enrollment. Study budgets routinely include line items for screening visits, lab processing, and per-patient completion fees. Almost none of them include a dedicated line for pre-screening coordination labor — the hours a CRC spends reviewing charts against inclusion/exclusion criteria before a single patient is ever contacted. That work is invisible in the budget and constant in practice.
WCG’s 2024 data flagged trial complexity as the number one challenge cited by sites, at 38%. Protocol complexity drives pre-screening labor up steeply: more criteria to cross-reference, more comorbidity exclusions to verify, more prior therapy wash-out windows to calculate. A site running a complex oncology protocol may spend forty-five minutes of coordinator time per potential patient just to determine the person is ineligible before contact. Multiply that across a pool of fifty flagged patients to find twelve screened, and the unpaid labor cost is substantial. Sites absorb it until they cannot, then they slow down identification to manage the workload — which reads on the sponsor dashboard as poor recruitment performance, not budget design failure.
The technology market has noticed this gap. The U.S. AI-based clinical trial patient matching market was valued at $1.1 billion in 2024, and platforms promising to automate eligibility pre-screening against EHR data have proliferated accordingly. The promise is real — automated chart review against I/E criteria can cut pre-screening time meaningfully. But the implementation reality at most community sites is that the platform requires integration with an EHR system that the site’s IT team has not prioritized, a data governance review that legal has not cleared, and a training workflow that the sponsor built for academic medical centers. The technology exists. The activation pathway does not.
That friction is not hypothetical. A site running five concurrent protocols, with a coordinator who handed in notice three weeks ago, does not have the bandwidth to onboard a new patient-matching platform mid-study. Sponsors who invest in recruitment technology without accounting for site-level implementation capacity are essentially purchasing a solution that sits in a vendor portal while their enrollment numbers stall.
What Changes Monday Morning
For site operations teams, the most immediate lever is a pre-screening workflow audit before the next study opens — not after the first enrollment call. Map the steps between CTMS eligibility flag and first patient contact attempt, and put a target time on each one. If the site cannot get from flag to first contact within 48 hours, the bottleneck is a process problem that needs fixing before a sponsor SIV, not a recruitment strategy conversation at week eight. ICH E6(R3) Section 5.2 places responsibility on investigators to maintain adequate resources for trial conduct — and coordinator workflow capacity is a resource question, not just a staffing headcount question.
For sponsors and CROs, the ask is sharper: add a recruitment workflow assessment to every site qualification visit, separate from the standard regulatory binder and staff training checklist. Ask the coordinator to walk through what happens between patient identification and first contact. Ask how long it takes. Ask what happens when she is the only person in the office and three protocols are in screening simultaneously. The answer tells you more about that site’s true enrollment capacity than any feasibility questionnaire — and it tells you where a pre-screening coordination budget line could actually move the needle.
The 59% figure in that survey should not be read as a recruitment marketing problem. It is a workflow design problem, and the sites carrying it are not failing — they are running on a model that was never built to succeed at the volume and complexity the current protocol landscape demands. The sponsors who recognize that distinction first will not just fill their trials faster; they will build site relationships that survive the next coordinator transition, the next amendment, and the next protocol that lands at the same network expecting the same results from the same broken process.
Watch for how CROs renegotiate site activation milestones over the next 18 months. If pre-screening labor starts appearing as a named deliverable in site contracts, that is the signal that the industry has finally decided to pay for the work it has always required.
References
- FierceBiotech — “Over half of clinical trial sites see recruitment hindered by inefficiencies: survey”
- WCG — “2024 Clinical Research Site Challenges Report”
- Tufts Center for the Study of Drug Development — “Day of Delay White Paper, August 2024”
- Ken Research — “US Artificial Intelligence Based Clinical Trial Solutions Patient Matching Market, 2024 Valuation”
